The claim references a specific study published in JAMA Network Open regarding 322 individuals in South Korea with early-onset Alzheimer's or FTD, and an average age of 62. While multiple web results reference JAMA Network Open and Alzheimer's studies, none of the provided evidence snippets contain the specific details (322 individuals, South Korea, average age of 62) to independently verify the entire claim. The evidence is insufficient to corroborate the specific parameters of the study.

The claim states that *all three* biomarkers accurately predicted decline in early-onset Alzheimer's patients. While the evidence confirms that these biomarkers are used to track progression and that they are relevant for Alzheimer's, the provided snippets do not contain the specific finding that *all three* accurately predicted decline in this specific patient group. This specific outcome appears to be derived from the original study mentioned in the claim, but it is not independently corroborated by the provided evidence.

The claim lists specific early warning signs of FTD (loss of empathy, impulsive decisions, poor judgment, etc.). While the web search results confirm that FTD affects behavior and personality, the provided evidence snippets do not list this specific combination of symptoms (loss of empathy, impulsive decisions, poor judgment, etc.) as a comprehensive set of early warning signs, making independent verification difficult. The evidence is suggestive but not fully corroborative of the specific list provided.